| Mrs Anna M Evans, APRN | |
|
111 Doctor Cir, Columbia, SC 29203-6502 | |
| (800) 491-0909 | |
| Not Available |
| Full Name | Mrs Anna M Evans |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 111 Doctor Cir, Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194264465 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 20613 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kershawhealth | Camden, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ies South Carolina Llc | 1355705070 | 16 |
| Musc Community Physicians | 6507260668 | 698 |
| Sc House Calls Inc | 6800994807 | 358 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Doctors Care, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366499048 PECOS PAC ID: 6204731300 Enrollment ID: O20040112000069 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Sc House Calls Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518048859 PECOS PAC ID: 6800994807 Enrollment ID: O20070613000821 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Apogee Medical Group South Carolina |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619028545 PECOS PAC ID: 8921193020 Enrollment ID: O20071004000474 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Providence Group Practices Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396192001 PECOS PAC ID: 2668768276 Enrollment ID: O20160908000669 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | App Of South Carolina Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457878084 PECOS PAC ID: 3577821107 Enrollment ID: O20180103000650 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Musc Community Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841878006 PECOS PAC ID: 6507260668 Enrollment ID: O20210811002388 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Entity Name | Ies South Carolina Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821779695 PECOS PAC ID: 1355705070 Enrollment ID: O20230914000885 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Anna M Evans, APRN 111 Doctor Cir, Columbia, SC 29203-6502 Ph: (800) 491-0909 | Mrs Anna M Evans, APRN 111 Doctor Cir, Columbia, SC 29203-6502 Ph: (800) 491-0909 |
News Archive
Scientists at The University of Manchester have used a new way of working to identify a new gene linked to neurodegenerative diseases such as Alzheimer's. The discovery fills in another piece of the jigsaw when it comes to identifying people most at risk of developing the condition.
By analyzing survey data from 1999-2001 and 2010-2012, researchers have estimated the demand for commercial sex among British men.
Results published in a new study in the Jan. 9 issue of the New England Journal of Medicine report that mild electronic stimulation therapy to the upper airway during sleep is effective in reducing obstructive sleep apnea (OSA).
Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, "Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity" at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.
› Verified 2 days ago
Mr. Joseph Crawford Iii, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 8 Richland Medical Park Dr Ste 300, Columbia, SC 29203 Phone: 803-256-6511 | |
Richard Hall Iii, APRN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Richland Medical Park Dr Ste 100, Columbia, SC 29203 Phone: 803-434-6095 Fax: 803-758-0120 | |
Latonya Brailsford, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4605 Monticello Rd Ste 2, Columbia, SC 29203 Phone: 803-753-5590 Fax: 803-753-5592 | |
Laketa D Riley, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 | |
Jenny O'neill, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 200 Arbor Lake Dr, Suite 120, Columbia, SC 29223 Phone: 803-457-8125 Fax: 803-457-8129 | |
Sarah Elizabeth Wilson, PNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 9 Richland Medical Park Dr Ste 420, Columbia, SC 29203 Phone: 803-434-3950 Fax: 803-434-3496 | |
Miss Karen Mccain, NURSE PRACTITONER Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 111 Doctor Cir, Columbia, SC 29203 Phone: 800-491-0909 |